Near-Infrared Light Devices Versus Landmark Approach for Peripheral Venous Access in Intensive Care Unit

Last updated: April 16, 2025
Sponsor: Centre Hospitalier Régional d'Orléans
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

near-infrared light device

Clinical Study ID

NCT06234293
CHRO-2022-14
  • Ages > 18
  • All Genders

Study Summary

The central venous catheter (CVC) is commonly used in intensive care unit (ICU). The primary complications associated with CVCs especially with prolonged use include thrombosis and infections. Hence, it is essential to remove the CVC as soon as it becomes unnecessary.

Peripheral intravenous cannulation (PIVC) on a critically ill patient can be a significant challenge for nurses. After several days in ICU, patients may develop significant edema in the upper limbs, complicating the PIVC.

Near-infrared light devices (NILD) are medical devices that use near-infrared light to highlight the patient's peripheral venous network directly on their skin. The advantage of this device is its minimal training and ease of use for effective application. Nurses can use this medical device without specific conditions once they have received training on its use. The vein illuminator has not been extensively studied in ICU.

This study aims to compare two techniques for PIVC in critically ill patients with existing CVC for whom maintaining the deep venous access is no longer indicated.

The investigators hypothesize that the use of the NILD would increase the success rate of first-attempt PIVC insertion compared to a landmark approach (traditional method) for PIVC in ICU.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • ≥18 years old

  • Hospitalized in ICU

  • with a deep venous catheter (jugular, subclavian or femoral)

  • In whom the use of a deep venous line is no longer justified (absence of:vasopressor amines, chemotherapy, parenteral nutrition, hypertonic solutions)

Exclusion

Exclusion Criteria:

  • Absolute contraindication or anatomical impossibility to perform a PIVC on the upperlimbs

  • Patient already included in the study

  • Tattoo covering most of both forearms

  • Adult subject to a legal protection measure (guardianship, curators, person undercourt protection)

  • Persons deprived of their liberty by a judicial or administrative decision, personshospitalised without consent and persons admitted to a health or socialestablishment for purposes other than research.

  • Pregnant or breast-feeding woman

Study Design

Total Participants: 380
Treatment Group(s): 1
Primary Treatment: near-infrared light device
Phase:
Study Start date:
February 28, 2024
Estimated Completion Date:
February 28, 2026

Study Description

This is a multicenter randomized controlled study. 380 patients will be randomly assigned with a 1:1 ratio to landmark approach (standard group) or near-infrared light device (interventional group).

Randomization will be done immediately after the enrollment of the patient. Randomization will be stratified by center and according to anticipated difficult venous access defined by:

  • BMI > 30 Kg/m2

  • Increase in body weight between admission and day of inclusion > 10%.

  • Clinically evident edema of the upper limbs (with pitting)

  • Absence of visible or palpable veins on arms and forearms If one or more items are present, the patient is classified as difficult to venous access.

Once the patient has been enrolled and randomized, the nurse in charge of the patient performs the PIVC according to the randomization group as soon as possible after randomization.

The nurse will have a maximum of 3 attempts before handing over to another nurse. The total number of attempts will be 5 with the allocated method (traditional method or NILD).

In the case of failure after 5 initial attempts, the intervention will be considered as a failure. However, a maximum of 5 additional attempts will be allowed with any method on the day of randomization. The success or failure of PIVC will be recorded, as well as the device used. The attempts should be performed within 6 hours after randomization.

If one of the 5 first initial attempts is successful, the study continues until the PIVC is removed (max 7 days according to recommendations) or patient discharge, whichever comes first, in order to evaluate the occurrence of local complications.

Connect with a study center

  • CH de Chartres

    Chartres,
    France

    Active - Recruiting

  • CH Le Mans

    Le Mans,
    France

    Active - Recruiting

  • CHU Orléans

    Orléans,
    France

    Active - Recruiting

  • CHU de Tours

    Tours,
    France

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.